Agoracom Blog Home

Posts Tagged ‘MIND MEDICINE (MINDMED) INC’

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:54 AM on Saturday, June 12th, 2021

A weekly summary of Novamind news and media, including the announcement of a new psychedelic therapy protocol for frontline healthcare workers.

FEATURES  June 7, 2021

A Quarter of Growth

Green Market Report covers our fiscal Q3 earnings in their Psychedellux recap of the top business stories in the psychedelic medicine industry.

Novamind reported total revenue of $1.8 million, a 43% quarter-over-quarter, driven by increased patient volume at the Company’s four operating clinics.

View all media

Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers

“Together with the Wholeness Center, we’re joining forces to offer a new therapy that will positively impact the people who show up every day and continue to provide critical healthcare for the public during—and after—this difficult time,” said Dr. Robison.

Click here to learn more about the Frontline KAP protocol

June 10, 2021

View all press releases

The Brain-Changing Magic of New Experiences

From GQ’s series on mental health comes a piece about the psychological reasons how new experiences can change how we perceive time and make us more resilient. It’s an interesting read and the author even compares trees blooming in spring to psychedelics. “Even the most mundane new experiences left me feeling genuinely elated.” There’s a reason for it too. From Dr. Laurie Santos, “Novel stimuli tend to activate regions of our brain that are associated with rewards.” At our Cedar Psychiatry clinics, we practice a holistic approach to mental health. Taking into account psychological, biological, social, environmental, and cultural influences. Learn more here.

Atai Life Sciences Announces Launch of Initial Public Offering

We’ve always believed in Atai’s vision to transform the treatment of mental health disorders. It’s why we became early strategic investment partners. Congratulations to Atai Life Sciences on launching their initial public offering. 

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:23 AM on Saturday, June 5th, 2021

A weekly summary of Novamind news and media, including a report of our fiscal Q3 financial results and operating highlights.

FEATURES  June 4, 2021

Psychedelic Healing,Here and Now

At Novamind, we’re preparing for the future of psychedelic medicine, but we’re also treating people today and the results have been life changing.

“This is the first treatment that’s ever given me any relief from suicidal ideations. It’s like they’re gone.”

FEATURES  June 1, 2021

More Than Just a Treatment for Depression

Novamind CMO Reid Robison speaks to the Toronto Sun about why ketamine is a game changer for treating eating disorders.

“I was sitting with people before, during and after treatment and I was blown away by what I saw. It’s not just a treatment for depression.”

FEATURES June 2, 2021

Growing at Scale

Behavioral Healthcare Executive covers our fiscal Q3 earnings report, detailing growth and forecasted clinic visits.

“Novamind, a mental health company that specializes in psychedelic medicine, this week announced revenues of $1.85 million for its fiscal quarter ending March 31, a 43% increase over the prior quarter. With its previously announced plans to open 4 new clinics, doubling the size of its network, between July and September, Novamind said in its earnings report that it expects to increase patient volume to more than 65,000 clinic visits in 2021, which would represent a 225% increase year-over-year.”

View all media

Novamind Reports Fiscal Q3 Financial Results and Operating Highlights

“Since listing on the CSE this January, Novamind has demonstrated its ability to rapidly scale access to innovative mental health treatment and psychedelic medicine,” said Yaron Conforti, CEO and Director, Novamind. “The contract with Merck to research a promising new drug, leveraged our expertise in patient recruitment and patient management. Novamind will continue to execute on its aggressive growth initiatives in 2021, further expanding organically and through acquisitions ahead of the FDA’s anticipated approvals of MDMA and psilocybin.” 

June 1, 2021

View all press releases

Researchers to Hone In On Most Therapeutic Doses of LSD

Identifying the correct dose for therapeutic settings is a crucial step in the path towards optimizing the healing power of psychedelics. In this article, Psychedelic Spotlight details new research studying the optimal LSD dosage for the treatment of mental health disorders. We look forward to more research and clinical trials in the future and will prepare for the time when LSD can be used as a treatment option in our clinics. 

The psychologists signing up for psychedelic therapy training: ‘Amazing things can happen’

The promise of psychedelic medicine is too great to ignore for Campbell Townsend, an Australian-based psychologist who is training in psychedelic-assisted psychotherapy. The Australian government has recently committed $15m to psychedelic clinical trials and support is growing in that country. There is significant momentum growing. Staying at the forefront of psychedelic research, Novamind is currently developing protocols for ketamine-assisted psychotherapy that will standardize and provide best-practice treatment methods for the widespread use of psychedelic medicine.

Follow @novamind_inc on Instagram

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:24 AM on Saturday, May 29th, 2021

A weekly summary of Novamind news and media

FEATURES May 28, 2021

Laying the groundwork for the psychedelic revolution

Novamind COO Pierre Bou-Mansour discusses rapid expansion, staying consistent and Novamind’s ultimate goal.

We want to set a new standard of mental healthcare, and be the network that patients prefer—to become a trusted partner for innovative mental healthcare.

View all media

How a psychedelic 12-step program is saving lives

Focused on creating a safe space “to incorporate psychedelic medicine into recovery,” Dimitri M. is a living embodiment of the wounded healer. A former heroin addict whose life was changed by Ibogaine and a 12-step program. Since he’s gone on to form Psychedelics in Recovery and is holding up to 17 meetings a week over zoom. Access to psychedelic medicine in the right situation can be life-changing. Dr. Reid Robison calls psychedelics “therapy accelerators.” Learn more about our innovative approach to psychedelic medicine here. 

MAPS wins appeal and authorization to study MDMA in healthy volunteer therapists

A study that had been on hold for almost two years has been approved. MAPS will hold a phase 1 clinical trial of MDMA-assisted therapy for healthcare workers. Working in conjunction with the FDA, MAPS was able to win the appeal and help “improve the regulatory landscape for all future patients of psychedelic-assisted medicines.” The study “will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients.” This study will address a critical area of need for healthcare workers. 

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:49 AM on Saturday, May 8th, 2021

A weekly summary of Novamind news and media

FEATURES May 7, 2021

Novamind Expands Footprint of Psychedelic Clinics

Our CEO Yaron Conforti and CMO Reid Robison discuss the news of our clinic expansion and how this further develops our model for scaling across the U.S.

FEATURES May 5, 2021

Pierre Bou-Mansour Discusses the Initial Phase of Novamind’s National Expansion Strategy

Our Chief Operating Officer speaks with the Wall Street Reporter about our clinic expansion, the key drivers of our growth, and the importance of set and setting in our clinics.

View all media

Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics

May 4, 2021

View all press releases

A Psychedelic Drug Passes Big Test for PTSD Treatment

In a soon-to-be-published study, MDMA and therapy are showing promising results in the treatment of PTSD, with over 67 percent of participants no longer qualifying for a diagnosis two months after treatment.

Why Psychedelics, Big in the 1960s, Are Drawing New Interest Now

Long misunderstood, psychedelics are back in the spotlight as more and more research is being done on the efficacy and positive mental health benefits they hold.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Novamind $NM.ca $NVMDF Doubles in Size, Adds Four New Psychedelic Mental Health Clinics $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:38 AM on Tuesday, May 4th, 2021
  • Announced that it will open four new Cedar Psychiatry clinics doubling its network to eight total locations
  • Begun construction on three of the New Clinics and leased a fourth additional property
  • Expanded capacity from the New Clinics is forecasted to increase Novamind’s patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021

New clinics represent the first phase of Novamind’s national expansion strategy

TORONTO, ON / May 4, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics (the “New Clinics”), doubling its network to eight total locations.

The expanded capacity from the New Clinics is forecasted to increase Novamind’s patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021, a 225% increase.

Novamind has begun construction on three of the New Clinics and leased a fourth additional property. Scheduled to open between July and September 2021, the New Clinics represent the initial phase of Novamind’s national expansion strategy whereby the Company is replicating the successful operating track record of its current clinics in Utah, at scale, ahead of its expansion into other American states in 2021.

Novamind’s investment in the expansion of its clinic network follows a significant increase in demand from clients for mental health services to address existing unmet needs and the effects of the Covid-19 pandemic. All Cedar Psychiatry clinics currently have a 2-week wait time for booking new appointments.

The New Clinics will each offer a range of treatments including ketamine-assisted psychotherapy, SpravatoTM, Cognitive Behavioral Therapy (CBT) and Transcranial Magnetic Stimulation (TMS). The Draper, Murray, and Salt Lake City locations will also offer opportunities for patients to participate in clinical trials for psychedelic medicine that are led by Cedar Clinical Research, Novamind’s clinical research arm. The Park City location will uniquely serve as both a clinic and a retreat center offering therapeutic psychedelic experiences, leveraging its community’s reputation as a world-class destination.

“We are doubling the size of our clinic network six months ahead of schedule, with the added capacity enabling us to scale to 65,000 client visits in 2021,” said Yaron Conforti, CEO and Director of Novamind. “Expect continued and aggressive growth as we expand Novamind’s clinic network and clinical research infrastructure ahead of the FDA’s anticipated approvals of MDMA and psilocybin.”

Novamind is making additional strategic investments in the infrastructure required to support the rapid growth in client volumes at its clinics. A new, dedicated call center is under construction and will enhance Novamind’s network of eight clinics by improving communications with clients and referring physicians, as well as facilitating the significant increase in processing of insurance reimbursements. Additional details for each of the New Clinics and the call center will be announced in subsequent press releases.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:56 AM on Saturday, April 24th, 2021

A weekly summary of Novamind news and media

FEATURES April 23, 2021

Dr. Reid Robison on the Science of Psychedelics

Leafy interviews Novamind’s CMO about how these compounds influence our mind on a molecular level.

FEATURES April 21, 2021

Why Merck Chose Novamind to Lead a Groundbreaking Study

Our CEO and CMO spoke with Streetwise Reports about how Cedar Clinical Research is positioned to develop a new option for treatment-resistant depression.

OPINION April 21, 2021

How Modern Psychedelics Began with a Bike Ride

On April 19, 1943, chemist Albert Hofmann took .00005 teaspoons of LSD. As he rode his bicycle home, he realized that the world had just changed. By Novamind CMO, Dr. Reid Robison and Kirsten Hirst.

View all media

Novamind Collaborates with Center for Change

April 21, 2021

Novamind Presented at the Planet MicroCap Virtual Event on April 22, 2021

April 19, 2021

Novamind Increases Strategic Investment in Bionomics

April 13, 2021

View all press releases

Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction

More Americans died from drug overdoses in 2020 than ever before. As psychedelic-assisted treatment options approach mainstream medicine, Time looks at ibogaine as a way to treat addiction like few treatments can.

Psychedelic Drug Worked As Well as Common Antidepressant, Small Trial Finds

Psilocybin works. Researchers in London released findings from a phase 2 trial indicating that a couple of doses of psilocybin may treat depression as well as one of the most commonly prescribed antidepressants. More research is required but leaders of the study were surprised with the outcome.

         Follow @novamind_inc on Instagram

Novamind $NM.ca $NVMDF Collaborates with Center for Change $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:54 AM on Wednesday, April 21st, 2021

Novamind working with Center for Change to treat patients, conduct research

  • Collaboration with Center for Change examines the novel use of Novamind’s ketamine-assisted psychotherapy (“KAP”) protocols for the treatment of eating disorders
  • Shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP)
  • There are no FDA-approved medication options currently available for individuals suffering from Anorexia Nervosa, an often-debilitating mental health condition

TORONTO, ON / April 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, has shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP). Novamind collaborated on the study with Center for Change, a specialty psychiatric hospital and leading treatment facility for eating disorders.

In a webinar held by Center for Change on April 8th, 2021, Dr. Reid Robison, Novamind’s Chief Medical Officer, discussed early findings from the two studies for eating disorders. The collaboration with Center for Change examines the novel use of Novamind’s ketamine-assisted psychotherapy (“KAP”) protocols for the treatment of eating disorders. There are no FDA-approved medication options currently available for individuals suffering from Anorexia Nervosa, an often-debilitating mental health condition.

“Novamind is dedicated to researching, developing and delivering new therapeutic protocols to answer unmet needs in mental healthcare,” said Dr. Robison, who also serves as Medical Director for Center for Change. “Our treatment protocols are designed to improve patient outcomes, and we’re proud that renowned facilities like Center for Change recognize that we can provide new options for individuals struggling with eating disorders.”

Novamind offers its clients access to several KAP protocols through Cedar Psychiatry, its wholly owned network of psychiatry clinics. Specialized KAP protocols currently available at Cedar Psychiatry include Emotion-Focused Ketamine-Assisted Psychotherapy and Group Ketamine-Assisted Psychotherapy. Cedar Psychiatry has administered over 7,000 ketamine treatments since 2016 and is undergoing an expansion of its clinic network in the United States.

“Novamind’s psychedelic protocols are informed by the expertise gained from our operating clinics, as well as collaborating with leading medical institutions. We’re pleased to work with Center for Change to advance innovation in mental healthcare,” said Yaron Conforti, CEO and Director of Novamind.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About Center for Change

Center for Change was founded on October 28th, 1994, by a team of psychologists and a physician with a long history together. From those first days, Center for Change began to design the current facility and develop its core treatment programs. A handpicked team of experts forms the backbone of what we do, and they are committed to helping each person get back their life and restore a sense of freedom that may have been absent for far too long.

The Center is licensed with the State of Utah as a Specialty Psychiatric Hospital, and in April 1998, Center for Change received accreditation from The Joint Commission. This accreditation is limited to top organizations delivering high levels of patient service, reducing patient risk and creating an environment for continuous improvement. The Joint Commission has recognized Center for Change for its high standards of patient care and commitment to ongoing education.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Center for Change
Tamara Bingham Noyes, Director of Business Development
Telephone: +1 (888) 224 8250 ext. 267
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

Novamind $NM.ca $NVMDF Announces Participation at the Planet MicroCap Showcase on April 20 – 22, 2021 $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 2:06 PM on Tuesday, April 20th, 2021
  • Will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

TORONTO, ON / April 20, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors. The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

Novamind will also be featured on a panel discussion titled, “Past, Present and Future of Psychedelics” on Tuesday, April 20th at 7:00 PM EST.

Presentation information:

To tune in to the webcast, please visit this link.

To book a one-on-one investor meeting with Novamind or to watch the Company’s presentation, please register for the virtual event here. One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies you want to know more about; read and watch content from your favorite finance and investing influencers; create your own watchlist and screen for ideas you’re interested in; find out about investor conferences you want to attend – all here on SNN.Network.

Contact Information:

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Novamind $NM.ca $NVMDF to Present at the Planet MicroCap Virtual Event on April 22, 2021 $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 12:18 PM on Monday, April 19th, 2021
  • Will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.
  • Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors.
  • The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

TORONTO, ON / April 19, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will present at the SNN Planet MicroCap Showcase on Thursday, April 22nd at 10:00 AM EST.

Yaron Conforti, Novamind’s CEO, will present at the event, outlining Novamind’s vision for scaling access to psychedelic medicine and taking questions from investors. The presentation will cover Novamind’s clinical and research infrastructure, recent milestones, and its expansion plans for 2021.

Novamind will also be featured on a panel discussion titled, “Past, Present and Future of Psychedelics” on Tuesday, April 20th at 7:00 PM EST.

Presentation information:

To tune in to the webcast, please visit this link.

To book a one-on-one investor meeting with Novamind or to watch the Company’s presentation, please register for the virtual event here. One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

SOURCE: Novamind Inc.

Novamind $NM.ca $NVMDF Increases Strategic Investment in Bionomics $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:37 AM on Tuesday, April 13th, 2021
  • Announced that it has increased its strategic investment in Bionomics Limited (“Bionomics”) (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
  • Investment supports phase IIb clinical trial examining novel PTSD treatment

TORONTO, ON / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has increased its strategic investment in Bionomics Limited (“Bionomics”) (ASX: BNO | OTCQB: BNOEF | Germany: AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.

Novamind purchased an additional 951,133 common shares at AU$0.145 per share for a total investment of AU$137,914 (approximately CAN$132,000) in Bionomics’ recently completed rights offering (the “Rights Offering”). In addition to Novamind’s initial AU$827,486 investment (approximately CAN$810,000) announced on February 11th, 2021, Novamind has invested in Bionomics a total of AU$965,400 (approximately CAN$942,000). Bionomics shares closed at AU$0.20 on April 12th, 2021, a 38% return (unrealized) on Novamind’s total investment.

Proceeds from the Rights Offering will support the initiation of Bionomics’ phase IIb clinical trial for BNC210, a drug that has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD). Bionomics is evaluating Cedar Clinical Research, a wholly owned subsidiary of Novamind, as a research site for the BNC210 clinical trial that is anticipated to start mid-2021.

“We are pleased to support the development of a new treatment for PTSD and to be evaluated as a clinical research site for the phase IIb clinical trial of BNC210,” said Yaron Conforti, CEO and Director of Novamind. “Our expertise in clinical research for mental health therapeutics is widely recognized in the biopharmaceutical industry, as demonstrated by our collaboration with Bionomics and recent partnership with Merck.”

To learn more about Cedar Clinical Research, please visit cedarclinicalresearch.com.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About Bionomics

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit bionomics.com.au.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.